These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16690321)

  • 1. p53 as a target for anti-cancer drug development.
    Bouchet BP; Caron de Fromentel C; Puisieux A; Galmarini CM
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):190-207. PubMed ID: 16690321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tumor suppressor gene TP53: implications for cancer management and therapy.
    Seemann S; Maurici D; Olivier M; Caron de Fromentel C; Hainaut P
    Crit Rev Clin Lab Sci; 2004; 41(5-6):551-83. PubMed ID: 15603511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.
    O'Shea CC; Johnson L; Bagus B; Choi S; Nicholas C; Shen A; Boyle L; Pandey K; Soria C; Kunich J; Shen Y; Habets G; Ginzinger D; McCormick F
    Cancer Cell; 2004 Dec; 6(6):611-23. PubMed ID: 15607965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.
    Hann B; Balmain A
    J Virol; 2003 Nov; 77(21):11588-95. PubMed ID: 14557644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and E1b-55kD-mediated degradation of p53.
    Sauthoff H; Pipiya T; Chen S; Heitner S; Cheng J; Huang YQ; Rom WN; Hay JG
    Cancer Gene Ther; 2006 Jul; 13(7):686-95. PubMed ID: 16470212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ONYX-015. Onyx Pharmaceuticals.
    Cohen EE; Rudin CM
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1770-5. PubMed ID: 11892945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
    Heise C; Lemmon M; Kirn D
    Clin Cancer Res; 2000 Dec; 6(12):4908-14. PubMed ID: 11156251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015.
    McCormick F
    Semin Cancer Biol; 2000 Dec; 10(6):453-9. PubMed ID: 11170867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene.
    Hay JG; Shapiro N; Sauthoff H; Heitner S; Phupakdi W; Rom WN
    Hum Gene Ther; 1999 Mar; 10(4):579-90. PubMed ID: 10094201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein.
    Shen Y; Kitzes G; Nye JA; Fattaey A; Hermiston T
    J Virol; 2001 May; 75(9):4297-307. PubMed ID: 11287579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy.
    O'Shea CC; Soria C; Bagus B; McCormick F
    Cancer Cell; 2005 Jul; 8(1):61-74. PubMed ID: 16023599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in adenovirus-mediated p53 cancer gene therapy.
    Tazawa H; Kagawa S; Fujiwara T
    Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smarter viruses. Onyx pharmaceuticals, Inc.
    Wells WA
    Chem Biol; 2000 Dec; 7(12):R223-4. PubMed ID: 11137823
    [No Abstract]   [Full Text] [Related]  

  • 15. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
    Nemunaitis J; Cunningham C; Tong A; Post L; Netto G; Paulson AS; Rich D; Blackburn A; Sands B; Gibson B; Randlev B; Freeman S
    Cancer Gene Ther; 2003 May; 10(5):341-52. PubMed ID: 12719704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterochromatin silencing of p53 target genes by a small viral protein.
    Soria C; Estermann FE; Espantman KC; O'Shea CC
    Nature; 2010 Aug; 466(7310):1076-81. PubMed ID: 20740008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?
    Dix BR; Edwards SJ; Braithwaite AW
    J Virol; 2001 Jun; 75(12):5443-7. PubMed ID: 11356950
    [No Abstract]   [Full Text] [Related]  

  • 19. Adenoviral gene therapy in head and neck cancer.
    Vattemi E; Claudio PP
    Drug News Perspect; 2006; 19(6):329-37. PubMed ID: 16971969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic E1B 55KDa-deleted adenovirus replication is independent of p53 levels in cancer cells.
    Abbas BM; El-Mogy MA; Haj-Ahmad Y
    Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(7):1-11. PubMed ID: 28838332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.